jueves, 29 de marzo de 2012
WHO Drug Information Vol. 26, No. 1, 2012
Contenido
Regulatory Focus
Regulation of medicines in China
Paediatric Medicines
Better medicines for children: pharmaceutical formulations
Benznidazole: child-adapted dosage form approved
Use of drugs in paediatric health conditions increasing
Safety and Efficacy Issues
Bevacizumab: severe infectious endophthalmitis and blindness
Ursodeoxycholic acid: serious hepatic events
Simvastatin with amiodarone: dosage review
Fenofibric acid: the ACCORD lipid trial
BCG vaccine: lymphadenitis
Dabigatran etexilate mesylate: bleeding events
Dabigatran etexilate: caution in the elderly and renally impaired
Dabigatran: risk of bleeding
Pneumovax 23®: revaccination recommendations
Somatropin-containing medicines: positive benefit-risk balance
Pholcodine-containing coughs medicines
Antipsychotics in children and adolescents: cardiometabolic reactions
Citalopram hydrobromide: dose dependent QT prolongation
Brentuximab vedotin: new warning and contraindication
Quetiapine: information updated
Aliskiren: cardiovascular and renal events
Natalizumab: progressive multifocal leukoencephalopathy
Boceprevir: HIV protease inhibitor interactions
Bortezomib: fatal if given intrathecally
Regulatory Action and News
Bevacizumab: suspension for metastatic breast cancer
Drotrecogin alfa: withdrawal
Dextropropoxyphene-containing analgesics cancelled
Vemurafenib approved for metastatic or unresectable melanoma
Ecallantide: marketing authorization application withdrawal
Sitagliptin and pioglitazone: marketing authorization application withdrawal
Voclosporin: marketing authorization application withdrawal
Desloratadine: marketing authorization application withdrawal
Electronic CTD implementation
ATC/DDD Classification
ATC/DDD Classification (temporary)
ATC/DDD Classification (final)
Recent Publications, Information and Events
Pharmacovigilance Toolkit
Uppsala Monitoring Centre signals document: increased availability
Learning module: selective serotonin reuptake inhibitors
Medicines access survey
ATC/DDD methodology course
Access and Control Newsletter
Managing access to medicines and health technologies
International Nonproprietary Names
ya está disponible en http://bit.ly/HNssvO
Etiquetas:
antipsicóticos,
benznidazol,
bevacizumab,
brentuximab,
China,
citalopram,
dabigatrán,
fenofibrato,
folcodina,
información de medicamentos,
OMS,
pediatría,
quetiapina
No hay comentarios:
Publicar un comentario